BRAF in metastatic colorectal cancer: The future starts now

Armando Orlandi, Maria Alessandra Calegari, Alessandro Inno, Rosa Berenato, Marta Caporale, Monica Niger, Ilaria Bossi, Maria Di Bartolomeo, Filippo De Braud, Filippo Pietrantonio

Research output: Contribution to journalArticlepeer-review


BRAF mutations are detectable in about 5-15% of metastatic colorectal cancer (mCRC) patients and represent a clear negative prognostic factor. While in BRAF-mutated (BRAFmt) metastatic melanoma TKI target therapies (BRAF and MEK inhibitor), both alone or in combination, have shown significant efficacy, in BRAFmt CRC single-agent BRAF-inhibitors as well as chemotherapy seem to be ineffective. The critical role of EGFR in CRC and its multiple downstreaming pathways seem to be involved in this lack of response. In recent years, preclinical investigations and retrospective studies slowly increased our knowledge on BRAFmt CRC. This review analyses preclinical data and discusses several clinical trials in order to explore new therapeutic strategies targeting BRAFmt mCRC.

Original languageEnglish
Pages (from-to)2069-2081
Number of pages13
Issue number18
Publication statusPublished - Dec 1 2015


  • BRAF
  • colorectal cancer
  • immunotherapy
  • target therapy

ASJC Scopus subject areas

  • Pharmacology
  • Genetics
  • Molecular Medicine


Dive into the research topics of 'BRAF in metastatic colorectal cancer: The future starts now'. Together they form a unique fingerprint.

Cite this